Kalaris Therapeutics filings document formal disclosures for a Nasdaq-listed clinical-stage biopharmaceutical company developing retinal-disease therapeutics. The record includes 8-K reports on operating and financial results, Regulation FD clinical presentations for TH103, material-event disclosures, capital-structure matters, and executive officer changes.
Proxy materials describe annual meeting and shareholder voting matters, while security disclosures identify Kalaris common stock under the KLRS ticker. Clinical disclosures focus on TH103 safety, tolerability, pharmacokinetics, early efficacy information, manufacturing updates, and the company's retinal-disease development plans.
Kalaris Therapeutics, Inc. reported a third-quarter 2026 net loss of $11.0 million, compared with $11.9 million in the prior-year quarter. Research and development expense was $8.3 million versus $9.1 million, and general and administrative expense was $3.5 million versus $3.6 million. Basic and diluted net loss per share was $0.46, compared with $0.64.
Cash, cash equivalents and marketable securities were $82.9 million as of September 30, 2026, versus $118.0 million as of December 31, 2025; the decrease primarily reflected cash used in operating activities. Based on current operating plans, Kalaris expects its September 30 balance to fund operations into 2028. Preliminary data from the ongoing Phase 1b/2 TH103 study in neovascular age-related macular degeneration are now expected in 2H 2027. The company completed technology transfer from a pilot to a commercial-scale manufacturer, with initial test batches meeting target specifications.
For the nine months ended September 30, 2026, net loss was $33.397 million, compared with $33.440 million for the same period of 2025.
For Kalaris Therapeutics, Inc. (KLRS), Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Matthew D. Perry each report beneficial ownership of 1,355,119 common shares, or 5.69% of the class. Each reports shared voting and dispositive power over that amount and zero sole voting or dispositive power; the shares are held directly by Coastlands Capital Partners LP. The 5.69% calculation uses 23,804,981 common shares outstanding as of August 4, 2026.
The Partnership says it holds the shares for its investors and has the right to receive, or direct receipt of, dividends and sale proceeds. The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interests.
Kalaris Therapeutics, Inc. (KLRS) reported that officer Amy O'Leary Vandekop, VP, Corporate Controller, received a grant of stock options for 10,000 shares of common stock. The options have an exercise price of $4.10 per share, expire on August 26, 2036, and vest over four years, with 25% vesting on August 1, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
Kalaris Therapeutics, Inc., a clinical-stage biotech focused on retinal diseases, reported continued losses as it advances lead anti-VEGF candidate TH103. For the quarter ended June 30, 2026, net loss was $11.5 million, and for the first half of 2026, net loss was $22.4 million, with no product revenue.
Quarterly operating expenses were $12.4 million, mainly research and development. Cash, cash equivalents and marketable securities totaled $93.5 million as of June 30, 2026, and management states this should fund operations for at least twelve months from the financial statement issuance date. Cash used in operations for the first half was $22.6 million.
The company carries a related-party royalty obligation of $32.1 million tied to UCSD-licensed technology and remains controlled by majority stockholder Samsara BioCapital. A prior reverse recapitalization with AlloVir reshaped the capital structure, and a $50.0 million private placement plus a $350.0 million shelf and $100.0 million at-the-market facility provide additional capital access. Material weaknesses in internal control over financial reporting are disclosed among key risks.
Kalaris Therapeutics, Inc. reported second quarter 2026 results and provided updates on its lead retinal therapy candidate TH103. Patient dosing is ongoing in a Phase 1b/2 trial in neovascular age-related macular degeneration, with preliminary data anticipated in the first half of 2027, and potential Phase 3 trials remain on track for initiation by year-end 2027.
As of June 30, 2026, Kalaris held $93.5 million in cash, cash equivalents and marketable securities, which it expects will fund operations into the fourth quarter of 2027 and through key clinical milestones. For the quarter ended June 30, 2026, research and development expenses were $9.0 million and general and administrative expenses were $3.4 million. Net loss for the quarter was $11.5 million, or $0.48 per share, compared with a net loss of $11.4 million, or $0.61 per share, for the same period in 2025.
Kalaris Therapeutics, Inc. reported that director Laurie Keating received a grant of stock options covering 18,000 shares of common stock, with a $3.51 exercise price and expiring on July 31, 2036. The options vest in equal monthly installments over three years from August 1, 2026 through August 1, 2029, subject to continuous service, resulting in 18,000 options directly held after this award.
Kalaris Therapeutics, Inc. reports that Laurie Keating is a director in an initial insider ownership statement. The report lists no transactions and shows no securities entries as beneficially owned in the data provided. Remarks reference Exhibit 24.1, described as a Power of Attorney.
Kalaris Therapeutics, Inc. officer Amy O'Leary Vandekop filed an initial statement of beneficial ownership. She reports direct ownership of 948 shares of common stock and two stock options over 27,415 shares at $7.31 expiring April 9, 2035 and 20,000 shares at $6.81 expiring March 18, 2036. Footnotes state the options were granted in April 2025 and March 2026, with 25% vesting on March 18, 2026 and March 19, 2027, respectively, and the remaining shares vesting in equal monthly installments through 2029 and 2030.
Kalaris Therapeutics, Inc. reported an equity compensation grant to its Chief Financial Officer, Liisa Ann Bayko. On July 20, 2026, she received a stock option to acquire 220,000 shares of common stock at an exercise price of $4.00 per share, expiring on July 19, 2036.
According to the vesting schedule, 25% of the underlying shares vest on July 20, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continuous service. Following this award, she holds options covering 220,000 shares.
Kalaris Therapeutics, Inc. lists Liisa Ann Bayko, its Chief Financial Officer, as a reporting person on Form 3. The Form 3 data show no equity holdings, derivative positions, or buy or sell transactions currently reported for her in Kalaris Therapeutics securities.